18 May 2026
Getty/agrobacterBy Olivia Bowthorpe
The first immunotherapy for a form of aggressive stomach cancer will be available on the NHS after NICE recommended the treatment.
More than 1,500 patients a year with operable gastric and gastro-oesophageal junction cancers are expected to be eligible for durvalumab, which will be given with standard chemotherapy and surgery.